Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Generic tenofovir disoproxil fumarate/emtricitabine the most frequently prescribed medication since 2021. (HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Historically, as mentioned, PrEP has been used to treat cisgender gay men, especially in light of the HIV crisis of the 1980s ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

The measure waives the need for a primary care physician’s prescription for HIV medications like PrEP and Doxy PEP.

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...